Cited by 279Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsMedical Imaging Techniques and Applications

Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer’s Disease Neuroimaging Initiative (ADNI)

Open access
Langbaum, Jessica B.S., Chen, Kewei, Lee, Wendy, Reschke, Cole, Bandy, Dan, Fleisher, Adam S., Alexander, Gene E., Foster, Norman L. +4 more·2009·NeuroImage

Abstract

In mostly small single-center studies, Alzheimer's disease (AD) is associated with characteristic and progressive reductions in fluorodeoxyglucose positron emission tomography (PET) measurements of the regional cerebral metabolic rate for glucose (CMRgl). The AD Neuroimaging Initiative (ADNI) is acquiring FDG PET, volumetric magnetic resonance imaging, and other biomarker measurements in a large longitudinal multi-center study of initially mildly affected probable AD (pAD) patients, amnestic mild cognitive impairment (aMCI) patients, who are at increased AD risk, and cognitively normal controls (NC), and we are responsible for analyzing the PET images using statistical parametric mapping (SPM). Here we compare baseline CMRgl measurements from 74 pAD patients and 142 aMCI patients to those from 82 NC, we correlate CMRgl with categorical and continuous measures of clinical disease severity, and we compare apolipoprotein E (APOE) varepsilon4 carriers to non-carriers in each of these subject groups. In comparison with NC, the pAD and aMCI groups each had significantly lower CMRgl bilaterally in posterior cingulate, precuneus, parietotemporal and frontal cortex. Similar reductions were observed when categories of disease severity or lower Mini-Mental State Exam (MMSE) scores were correlated with lower CMRgl. However, when analyses were restricted to the pAD patients, lower MMSE scores were significantly correlated with lower left frontal and temporal CMRgl. These findings from a large, multi-site study support previous single-site findings, supports the characteristic pattern of baseline CMRgl reductions in AD and aMCI patients, as well as preferential anterior CMRgl reductions after the onset of AD dementia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuroimage.2008.12.072

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Peripheral insulin resistance also occurs in the central nervous system.

    “Peripheral resistance to insulin also occurs in the CNS, as the glucose metabolic rate is reduced in the brains of AD patients in fluorodeoxyglucose positron emission tomography (FDG PET) [118,119].”

    From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [118]

  • In Alzheimer's disease patients, the brain glucose metabolic rate is reduced as measured by fluorodeoxyglucose positron emission tomography (FDG PET).

    “Peripheral resistance to insulin also occurs in the CNS, as the glucose metabolic rate is reduced in the brains of AD patients in fluorodeoxyglucose positron emission tomography (FDG PET) [118,119].”

    From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [118]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 59 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. De SS de Leon MJ Rusinek H Convit A Tarshish CY Roche A Tsui WH Kandil E Boppana M Daisley K Wang GJ Schlyer D Fowler J 2001 Hippocampal formation glucose metabolism and volume losses in MCI and AD Neurobiol Aging 22 529 539 11445252
  2. Mosconi L De SS Li J Tsui WH Li Y Boppana M Laska E Rusinek H de Leon MJ 2008a Hippocampal hypometabolism predicts cognitive decline from normal aging Neurobiol Aging 29 676 692 17222480 PMC2430185

Cited by

Sorted by citations

Authors
Langbaum, J. B. S., Chen, K., Lee, W., Reschke, C., Bandy, D., Fleisher, A. S., Alexander, G. E., Foster, N. L., Weiner, M. W., Koeppe, R. A., Jagust, W. J., & Reiman, E. M.
Affiliations
  • Banner Alzheimer’s Institute (US)
  • University of Arizona (US)
  • University of California San Diego (US)
  • University of Utah (US)
  • San Francisco VA Medical Center (US)
  • University of Michigan (US)
  • University of California, Berkeley (US)
  • Translational Genomics Research Institute (US)
Corresponding author
Reiman, Eric M.
Venue
NeuroImage
Publisher
Elsevier BV
Published
2009-05
Volume
45
Issue
4
Pages
1107-1116
ISSN
1053-8119 (ISSN-L)
OpenAlex
W2016228161
Cited by
279
References
59
Citations by year
2026: 5 · 2025: 8 · 2024: 10 · 2023: 6 · 2022: 8 · 2021: 9 · 2020: 8 · 2019: 11 · 2018: 26 · 2017: 14 · 2016: 21 · 2015: 15 · 2014: 22 · 2013: 26 · 2012: 24
FWCI
18.55
Type
journal article
Language
en
Open access
Locations
  • NeuroImage (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (5u01ag024904-10)
  • National Institute on Aging (U01-AG-024904, P30AG019610, U19AG010483)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
Alzheimer's disease, amnestic mild cognitive impairment, FDG-PET, regional cerebral glucose metabolism, posterior cingulate cortex, precuneus, frontal and temporal cortex, disease severity, Mini-Mental State Examination, APOE ε4, ADNI
MeSH terms
Aged, Alzheimer Disease, Cerebral Cortex, Cognition Disorders, Female, Humans, Male, Middle Aged, Reference Values, Sensitivity and Specificity, Statistics as Topic, Reproducibility of Results, Radiopharmaceuticals, Fluorodeoxyglucose F18, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review